Knowde Enhanced TDS
Identification & Functionality
- Ingredient Name
- Food Ingredients Functions
- Pharma & Nutraceuticals Functions
- Ingredients
- Lactobacillus Rhamnosus
- Product Families
- Strain Origin and History
Vivoflora’s Lactobacillus rhamnosus LB3™ strain was isolated from a plant extract derived from pharmaceutical herbs.
Features & Benefits
- Attributes
Functional Characteristics and Efficacy
Vivoflora’s Lactobacillus rhamnosus LB3TM strain assists the restoration and balancing of intestinal microbiota. It exhibits strong inhibition of the growth of pathogenic bacteria and fungi and the production of high levels of proteolytic enzymes for assistance with protein digestion and food allergies. The LB3 strain also demonstrates the induction of specific antibody production, balancing of the immune system by stimulation or production of key cytokines such as IFNs, TNF, and NK cells for protection against viruses and cancer cells, the ability to decrease mutagenic impact, and an increase in level of mitochondria function.Digestive Health Functionality
The L. rhamnosus LB3™ form of Lactobacillus rhamnosus has high levels of survival in the human intestine as well as high resistance to bile salts, gastrointestinal enzymes and acids, and exhibits good adhesion properties in vivo. This strain also exhibits high levels of proteolytic activity to allow for better digestion of both plant and animal protein.Protective Functionality
Vivoflora’s Lactobacillus rhamnosus LB3™ strain has strong antagonistic activity against a broad spectrum of pathogenic and conditionally-pathogenic microbes to create a favorable environment for development of useful gastrointestinal bacteria and stimulates growth of native microbiota to restore normal levels to the host. This strain also competes well for binding sites in the intestinal mucosa even in the presence of widely used antibiotics to prevent the gut lining from being compromised. In particular, the LB3 strain exhibits high levels of antagonistic activity against Gram Positive and Gram Negative pathogens including those found in hospital infections, post operative infections and complications as well as antagonistic activity against food spoilage organisms. This strain has a high level of antagonistic activity against a wide spectrum of yeasts, fungus, as well as a very high level of anti-Candida activity. The L. rhamnosus LB3 form of Lactobacillus rhamnosus also maintains antagonistic activity in the presence of antibiotics. Immune Modulation The L. rhamnosus LB3™ form of Lactobacillus rhamnosus has the ability to affect innate and adaptive immunity through both specific and non-specific links thus controlling coordination of the immune response by TH1 and Th2 pathways depending upon the immune status of the subject. This strain also balances the immune system through the stimulation or production of key cytokines such as IFNs, TNF, and NK cells which consequently aid in protection against viruses and cancer cells. The LB3 strain also stimulates a humoral immune response, the body’s ability to produce immunoglobulins and other naturally occurring antibodies.Anti-Mutagenic, Antibiotic Tolerant, and Detoxification Properties
Vivoflora’s Lactobacillus rhamnosus LB3TM strain shows strong resistance to chemotherapy drugs, a high level of adhesion in vivo in the presence of chemotherapy drugs, and demonstrates high anti-mutagenic and detoxification activity. The LB3 strain also works well alongside known antibiotics and exhibits good adhesion and immune stimulating ability in their presence.
Applications & Uses
- Markets
- Food & Nutrition Applications
- Target Application
Perfect strain for special foods or supplements to protect and fight infections and digestion problems.
Regulatory & Compliance
- Certifications & Compliance
- Strain Authenticity & Deposit
According to FAO/WHO, the Vivoflora’s Lactobacillus rhamnosus LB3TM strain has been identified as Lactobacillus rhamnosus on the basis of phenotype, carbohydrate utilization or fermentation profile, and genetic ribotype technique. This strain is deposited in the Ukranian Strain Collection of Industrial Microorganisms as L. rhamnosus IMV B-7038.
Technical Details & Test Data
- Clinical Studies
The L. rhamnosus LB3™ form of Lactobacillus rhamnosus alone and in probiotic composition with the L. delbrueckii LETM form of L. delbrueckii, was clinically used for patients with different otolaryngology infections, including Candida and viruses, digestion and immune problems with 85-95% positive immune profiles. Clinical testing was done in the Hospital of Institute of Otolaryngology Academy of Medical Sciences, Kiev, 2002-2006, for State Program “New Probiotics for Otolaryngology”.
Safety & Health
- Safety Assessment
A safety assessment has been performed for acute and chronic toxicity using rats and mice. The LD50 in acute testing was 18g/kg body mass. Lactobacillus rhamnosus is a strain that has been commonly used since prior to 1994 and its safe use in dietary supplements is FDA compliant under the Dietary Supplement Health and Education Act of 1994 (DSHEA).